BioSpace News Archive

Do You Think You’re Being Set up for Failure at Work? Here’s How to Handle It!

Do you have a strong feeling that people or forces are conspiring against you at work? Have you noticed that some of your colleagues withhold information or resources necessary for you to reach your goals?

February 27, 2019

·

3 min read

·

Porschia Parker

Deals

Gene Therapy Market Heats up as Sarepta Buys Myonexus for $165 Million

As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.

February 27, 2019

·

2 min read

·

Mark Terry

Policy

FDA Unveils New Steps to Address the Opioid Crisis

FDA Commissioner Scott Gottlieb said the agency has changed its approach to the opioid crisis and will take a more aggressive approach on regulatory actions.

February 27, 2019

·

3 min read

·

Alex Keown

Policy

FDA Advisory Panel Recommends Waiting for More Data Before Approving Karyopharm’s Selinexor

Shares of Karyopharm Therapeutics are crashing again after an advisory panel from the U.S. Food and Drug Administration recommended delaying potential approval of the company’s experimental multiple myeloma treatment until additional data is available from an ongoing Phase III study.

February 27, 2019

·

3 min read

·

Alex Keown

Business

Novartis and Blackstone Launch Anthos Therapeutics With $250 Million

Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.

February 27, 2019

·

3 min read

·

Mark Terry

Policy

Second Lawsuit Alleging Bayer’s Roundup Led to the Development of Cancer Begins

Could a product in a weed killer contribute to the development of a cancer? That is the question a jury will answer as Bayer faces accusations that glyphosate, the active ingredient in its top=selling weed killer Roundup, caused cancer in some individuals who have used the product.

February 27, 2019

·

3 min read

·

Alex Keown

Why Bristol-Myers' Future is Highly Dependent on T

Business

Bristol-Myers Squibb Pulls 3 Programs out of CytomX Partnership

Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional targets using CytomX’s Probody platform.

February 27, 2019

·

3 min read

·

Mark Terry

Policy

FDA Issues Refusal to File Letter for Adamis’ Alternative to Cialis

Shares of Adamis Pharmaceuticals are down nearly 5 percent this morning after the company announced late Tuesday that the U.S. Food and Drug Administration rejected its sublingual tadalafil product for erectile dysfunction, an alternative to the blockbuster Cialis.

February 27, 2019

·

2 min read

·

Alex Keown

Policy

BioSpace’s Global Biopharma Roundup: Feb. 28

BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.

February 27, 2019

·

4 min read

·

Alex Keown

Business

Abcam Moves to New Purpose-Built Global Headquarters

Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus, UK, a leading hub of healthcare, science and medical research.

February 27, 2019

·

2 min read